BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

Core Insights - BridgeBio Pharma, Inc. announced that outcomes data from the ongoing long-term open-label extension of its Phase 3 study of acoramidis in ATTR-CM will be presented at the AHA Scientific Sessions in November 2024 [1] - The company will also share three moderated digital posters related to ATTR-CM during the conference [1] Presentation Details - The featured science oral presentation will focus on how acoramidis reduces all-cause mortality and cardiovascular-related hospitalization, presented by Dr. Daniel Judge on November 18, 2024 [2] - The moderated digital posters will cover various topics, including healthcare resource utilization in transthyretin amyloid cardiomyopathy and evolving baseline risk in patients [2] Company Overview - BridgeBio Pharma is a commercial-stage biopharmaceutical company founded in 2015, dedicated to developing transformative medicines for genetic diseases [3] - The company’s pipeline includes a range of development programs from early science to advanced clinical trials [3]